Fever, rash, and systemic symptoms: Understanding the role of virus and HLA in severe cutaneous drug allergy

Journal of Allergy and Clinical Immunology: In Practice

Volumn 2, Issue 1, 2014, Pages 21-33

  Pavlos, Rebecca ^a   Mallal, Simon ^a,b   Ostrov, David ^c   Pompeu, Yuri ^c   Phillips, Elizabeth ^a,b  

^a MURDOCH UNIVERSITY   (Australia)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Abacavir; Carbamazepine; DRESS DIHS HSS; HLA; SJS TEN; Viral reactivation

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ACICLOVIR; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; CARBAMAZEPINE; CODEINE; CORTICOSTEROID; FLUCLOXACILLIN; HLA ANTIGEN; IMMUNOGLOBULIN; INDINAVIR; INDOMETACIN; LAMIVUDINE; STEROID; ZIDOVUDINE;

ABACAVIR HYPERSENSITIVITY SYNDROME; ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLELE; ARTICLE; DISEASE ASSOCIATION; DISEASE MODEL; DISORDERS OF LIPID METABOLISM; DRESS SYNDROME; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FAT REDISTRIBUTION; FEVER; GENETIC ASSOCIATION; GENETIC SCREENING; GENITAL LESION; GENITAL SYSTEM DISEASE; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOPATHOGENESIS; LIVER DYSFUNCTION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUTH LESION; NAUSEA; PATCH TEST; PHENOTYPE; RASH; SEVERE CUTANEOUS DRUG ALLERGY; SORE THROAT; STEVENS JOHNSON SYNDROME; SYMPTOM; TOXIC EPIDERMAL NECROLYSIS; UNSPECIFIED SIDE EFFECT; VIRUS REACTIVATION;

ABACAVIR; ABC; ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ADR; ADVERSE DRUG REACTION; AGEP; BID; CARBAMAZEPINE; CBZ; CMV; CTL; CYTOMEGALOVIRUS; CYTOTOXIC LYMPHOCYTE; DIHS; DRESS; DRESS-DIHS-HSS; DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS; DRUG-INDUCED HYPERSENSITIVITY SYNDROME; EBV; EPSTEIN-BARR VIRUS; HHV; HLA; HSR; HSS; HUMAN HERPESVIRUS; HUMAN LEUKOCYTE ANTIGEN; HYPERSENSITIVITY REACTION; HYPERSENSITIVITY SYNDROME; INF-Γ; INTERFERON GAMMA; NONSTEROIDAL ANTI-INFLAMMATORY DRUG; NSAID; ORALLY; PBMC; PERIPHERAL BLOOD MONONUCLEAR CELL; PO; SCAR; SEVERE CUTANEOUS ADVERSE DRUG REACTION; SJS; SJS-TEN; STEVEN-JOHNSON SYNDROME; T-CELL RECEPTOR; TCR; TEN; TOXIC EPIDERMAL NECROLYSIS; TWICE A DAY; VIRAL REACTIVATION;

ADULT; ANTICONVULSANTS; CARBAMAZEPINE; CYTOMEGALOVIRUS; DIDEOXYNUCLEOSIDES; DRUG HYPERSENSITIVITY SYNDROME; EXANTHEMA; FEMALE; FEVER; HERPESVIRUS 2, HUMAN; HERPESVIRUS 3, HUMAN; HIV-1; HLA ANTIGENS; HUMANS; PROGNOSIS; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SKIN TESTS; STEVENS-JOHNSON SYNDROME; VIRUS ACTIVATION; VIRUSES;

EID: 84891651331     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2013.11.005     Document Type: Article

References (173)

1. Pirmohamed M., Aithal G.P., Behr E., Daly A., Roden D. The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions. Clin Pharmacol Ther 2011, 89:784-785.
2. Hotz C., Valeyrie-Allanore L., Haddad C., Bouvresse S., Ortonne N., Duong T.A., et al. Systemic involvement of acute generalized exanthematous pustulosis: a retrospective study on 58 patients. Br J Dermatol 2013, 169:1223-1232.
3. Sidoroff A., Halevy S., Bavinck J.N., Vaillant L., Roujeau J.C. Acute generalized exanthematous pustulosis (AGEP): a clinical reaction pattern. J Cutan Pathol 2001, 28:113-119.
4. Speeckaert M.M., Speeckaert R., Lambert J., Brochez L. Acute generalized exanthematous pustulosis: an overview of the clinical, immunological and diagnostic concepts. Eur J Dermatol 2010, 20:425-433.
5. Raison-Peyron N. "Cutaneous adverse drug reactions" are not always drug-induced. Eur J Dermatol 2013, 23:439-442.
6. Feio A.B., Apetato M., Costa M.M., Sa J., Alcantara J. Acute generalized exanthematous pustulosis due to Coxsackie B4 virus [in Portuguese]. Acta Med Port 1997, 10:487-491.
7. Haro-Gabaldon V., Sanchez-Sanchez-Vizcaino J., Ruiz-Avila P., Gutierrez-Fernandez J., Linares J., Naranjo-Sintes R. Acute generalized exanthematous pustulosis with cytomegalovirus infection. Int J Dermatol 1996, 35:735-737.
8. Klein N., Hartmann M., Helmbold P., Enk A. Acute generalized exanthematous pustulosis associated with recurrent urinary tract infections [in German with English abstract]. Hautarzt 2009, 60:226-228.
9. Manzano S., Guggisberg D., Hammann C., Laubscher B. Acute generalized exanthematous pustulosis: first case associated with a Chlamydia pneumoniae infection [in French with English abstract ]. Arch Pediatr 2006, 13:1230-1232.
10. Naides S.J. Rheumatic manifestations of parvovirus B19 infection. Rheum Dis Clin North Am 1998, 24:375-401.
11. Bernard P., Lizeveaux-Parneix V., Miossec V., Bonnetblanc J., Drouet M. HLA et prédisposition génétique dans les pustuloses exanthématiques aiguës généralisées (PEAG) et dans les exanthèmes maculo-papuleux (EMP). Ann Dermatol Venereol 1995, 122:S38-S39.
12. Tohyama M., Hashimoto K. New aspects of drug-induced hypersensitivity syndrome. J Dermatol 2011, 38:222-228.
13. Tohyama M., Hashimoto K., Yasukawa M., Kimura H., Horikawa T., Nakajima K., et al. Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome. Br J Dermatol 2007, 157:934-940.
14. Pavlos R., Mallal S., Phillips E. HLA and pharmacogenetics of drug hypersensitivity. Pharmacogenomics 2012, 13:1285-1306.
15. Martin A.M., Nolan D., James I., Cameron P., Keller J., Moore C., et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS 2005, 19:97-99.
16. Phillips EBJ, Sanne I, Lederman M, Hinkle J, Rousseau F, James I, et al. Associations between HLA-DRBA*0102, HLA-B*5801 and hepatotoxicity in patients who initiated nevirapine containing regimens in South Africa. 18th Conference on retroviruses and opportunistic infections. Paper #949. Boston, MA; February 2011.
17. Yuan J., Guo S., Hall D., Cammett A.M., Jayadev S., Distel M., et al. Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. AIDS 2011, 25:1271-1280.
18. Phillips E., Bartlett J.A., Sanne I., Lederman M.M., Hinkle J., Rousseau F., et al. Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. J Acquir Immune Defic Syndr 2013, 62:e55-e57.
19. Littera R., Carcassi C., Masala A., Piano P., Serra P., Ortu F., et al. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS 2006, 20:1621-1626.
20. Gatanaga H., Yazaki H., Tanuma J., Honda M., Genka I., Teruya K., et al. HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS 2007, 21:264-265.
21. Gao S., Gui X.E., Liang K., Liu Z., Hu J., Dong B. HLA-dependent hypersensitivity reaction to nevirapine in chinese han hiv-infected patients. AIDS Res Hum Retroviruses 2011, 28:540-543.
22. Carr D.F., Chaponda M., Jorgensen A.L., Castro E.C., van Oosterhout J.J., Khoo S.H., et al. Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population. Clin Infect Dis 2013, 56:1330-1339.
23. Cutrell A.G., Hernandez J.E., Fleming J.W., Edwards M.T., Moore M.A., Brothers C.H., et al. Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir. Ann Pharmacother 2004, 38:2171-2172.
24. Symonds W., Cutrell A., Edwards M., Steel H., Spreen B., Powell G., et al. Risk factor analysis of hypersensitivity reactions to abacavir. Clin Ther 2002, 24:565-573.
25. Hetherington S., Hughes A.R., Mosteller M., Shortino D., Baker K.L., Spreen W., et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002, 359:1121-1122.
26. Mallal S., Nolan D., Witt C., Masel G., Martin A.M., Moore C., et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002, 359:727-732.
27. Phillips E.J., Wong G.A., Kaul R., Shahabi K., Nolan D.A., Knowles S.R., et al. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS 2005, 19:979-981.
28. Mallal S., Phillips E., Carosi G., Molina J.M., Workman C., Tomazic J., et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008, 358:568-579.
29. Phillips ESS, Arribas J, Fitch N, Givens N. Characteristics of abacavir hypersensitivity diagnoses according to HLA-B*5701 status and subsequent abacavir patch test result. 11th European AIDS Conference. Madrid, Spain. 2007:P9.7/04.
30. Saag M., Balu R., Phillips E., Brachman P., Martorell C., Burman W., et al. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis 2008, 46:1111-1118.
31. Martin M.A., Klein T.E., Dong B.J., Pirmohamed M., Haas D.W., Kroetz D.L. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin Pharmacol Ther 2012, 91:734-738.
32. Hughes D.A., Vilar F.J., Ward C.C., Alfirevic A., Park B.K., Pirmohamed M. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 2004, 14:335-342.
33. Schackman B.R., Scott C.A., Walensky R.P., Losina E., Freedberg K.A., Sax P.E. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 2008, 22:2025-2033.
34. Phillips E.J., Sullivan J.R., Knowles S.R., Shear N.H. Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. AIDS 2002, 16:2223-2225.
35. Almeida C.A., Martin A.M., Nolan D., Lucas A., Cameron P.U., James I., et al. Cytokine profiling in abacavir hypersensitivity patients. Antivir Ther 2008, 13:281-288.
36. Martin A.M., Almeida C.A., Cameron P., Purcell A.W., Nolan D., James I., et al. Immune responses to abacavir in antigen-presenting cells from hypersensitive patients. AIDS 2007, 21:1233-1244.
37. Chessman D., Kostenko L., Lethborg T., Purcell A.W., Williamson N.A., Chen Z., et al. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 2008, 28:822-832.
38. Chung W.H., Hung S.I., Hong H.S., Hsih M.S., Yang L.C., Ho H.C., et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004, 428:486.
39. Hung S.I., Chung W.H., Jee S.H., Chen W.C., Chang Y.T., Lee W.R., et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006, 16:297-306.
40. Kulkantrakorn K., Tassaneeyakul W., Tiamkao S., Jantararoungtong T., Prabmechai N., Vannaprasaht S., et al. HLA-B*1502 Strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain. Pain Pract 2011, 12:202-208.
41. Likanonsakul S., Rattanatham T., Feangvad S., Uttayamakul S., Prasithsirikul W., Tunthanathip P., et al. HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients. AIDS Res Ther 2009, 6:22.
42. Mehta T.Y., Prajapati L.M., Mittal B., Joshi C.G., Sheth J.J., Patel D.B., et al. Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol 2009, 75:579-582.
43. Tassaneeyakul W., Tiamkao S., Jantararoungtong T., Chen P., Lin S.Y., Chen W.H., et al. Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia 2010, 51:926-930.
44. Then S.M., Rani Z.Z., Raymond A.A., Ratnaningrum S., Jamal R. Frequency of the HLA-B*1502 allele contributing to carbamazepine-induced hypersensitivity reactions in a cohort of Malaysian epilepsy patients. Asian Pac J Allergy Immunol 2011, 29:290-293.
45. Kim S.H., Lee K.W., Song W.J., Jee Y.K., Lee S.M., Kang H.R., et al. Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans. Epilepsy Res 2011, 97:190-197.
46. Chen P., Lin J.J., Lu C.S., Ong C.T., Hsieh P.F., Yang C.C., et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 2011, 364:1126-1133.
47. Amstutz U., Ross C.J., Castro-Pastrana L.I., Rieder M.J., Shear N.H., Hayden M.R., et al. HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children. Clin Pharmacol Ther 2013, 94:142-149.
48. McCormack M., Alfirevic A., Bourgeois S., Farrell J.J., Kasperaviciute D., Carrington M., et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011, 364:1134-1143.
49. Ozeki T., Mushiroda T., Yowang A., Takahashi A., Kubo M., Shirakata Y., et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in a Japanese population. Hum Mol Genet 2011, 20:1034-1041.
50. Ko T.M., Chung W.H., Wei C.Y., Shih H.Y., Chen J.K., Lin C.H., et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol 2011, 128:1266. 76.e11.
51. Park B.K., Naisbitt D.J., Gordon S.F., Kitteringham N.R., Pirmohamed M. Metabolic activation in drug allergies. Toxicology 2001, 158:11-23.
52. Pichler W.J., Beeler A., Keller M., Lerch M., Posadas S., Schmid D., et al. Pharmacological interaction of drugs with immune receptors: the p-i concept. Allergol Int 2006, 55:17-25.
53. Illing P.T., Vivian J.P., Dudek N.L., Kostenko L., Chen Z., Bharadwaj M., et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 2012, 486:554-558.
54. Ostrov D.A., Grant B.J., Pompeu Y.A., Sidney J., Harndahl M., Southwood S., et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci U S A 2012, 109:9959-9964.
55. Norcross M.A., Luo S., Lu L., Boyne M.T., Gomartelli M., Rennels A.D., et al. Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity. AIDS 2012, 26:F21-9.
56. Wei C.Y., Chung W.H., Huang H.W., Chen Y.T., Hung S.I. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. J Allergy Clin Immunol 2012, 129:1562-1569.
57. Kano Y., Inaoka M., Shiohara T. Association between anticonvulsant hypersensitivity syndrome and human herpesvirus 6 reactivation and hypogammaglobulinemia. Arch Dermatol 2004, 140:183-188.
58. Descamps V., Valance A., Edlinger C., Fillet A.M., Grossin M., Lebrun-Vignes B., et al. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol 2001, 137:301-304.
59. Kano Y., Hiraharas K., Sakuma K., Shiohara T. Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease. Br J Dermatol 2006, 155:301-306.
60. Seishima M., Yamanaka S., Fujisawa T., Tohyama M., Hashimoto K. Reactivation of human herpesvirus (HHV) family members other than HHV-6 in drug-induced hypersensitivity syndrome. Br J Dermatol 2006, 155:344-349.
61. Shiohara T., Inaoka M., Kano Y. Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. Allergol Int 2006, 55:1-8.
62. Picard D., Janela B., Descamps V., D'Incan M., Courville P., Jacquot S., et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. Sci Transl Med 2010, 2. 46ra62.
63. Ushigome Y., Kano Y., Ishida T., Hirahara K., Shiohara T. Short- and long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution. J Am Acad Dermatol 2013, 68:721-728.
64. Aihara M., Sugita Y., Takahashi S., Nagatani T., Arata S., Takeuchi K., et al. Anticonvulsant hypersensitivity syndrome associated with reactivation of cytomegalovirus. Br J Dermatol 2001, 144:1231-1234.
65. Descamps V., Mahe E., Houhou N., Abramowitz L., Rozenberg F., Ranger-Rogez S., et al. Drug-induced hypersensitivity syndrome associated with Epstein-Barr virus infection. Br J Dermatol 2003, 148:1032-1034.
66. Harding D.J., Subramaniam K., MacQuillan G., Davis J., Nolan D. Severe drug-induced hypersensitivity syndrome with a shared HLA-B allele. Med J Aust 2012, 197:411-413.
67. Aota N., Hirahara K., Kano Y., Fukuoka T., Yamada A., Shiohara T. Systemic lupus erythematosus presenting with Kikuchi-Fujimoto's disease as a long-term sequela of drug-induced hypersensitivity syndrome. A possible role of Epstein-Barr virus reactivation. Dermatology 2009, 218:275-277.
68. Chiou C.C., Chung W.H., Hung S.I., Yang L.C., Hong H.S. Fulminant type 1 diabetes mellitus caused by drug hypersensitivity syndrome with human herpesvirus 6 infection. J Am Acad Dermatol 2006, 54:S14-S17.
69. Kano Y., Sakuma K., Shiohara T. Sclerodermoid graft-versus-host disease-like lesions occurring after drug-induced hypersensitivity syndrome. Br J Dermatol 2007, 156:1061-1063.
70. Sekine N., Motokura T., Oki T., Umeda Y., Sasaki N., Hayashi M., et al. Rapid loss of insulin secretion in a patient with fulminant type 1 diabetes mellitus and carbamazepine hypersensitivity syndrome. JAMA 2001, 285:1153-1154.
71. Takahashi R., Kano Y., Yamazaki Y., Kimishima M., Mizukawa Y., Shiohara T. Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome. J Immunol 2009, 182:8071-8079.
72. Chen Y.C., Chang C.Y., Cho Y.T., Chiu H.C., Chu C.Y. Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: a retrospective cohort study from Taiwan. J Am Acad Dermatol 2013, 68:459-465.
73. Burrows S.R., Khanna R., Burrows J.M., Moss D.J. An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-versus-host disease. J Exp Med 1994, 179:1155-1161.
74. Gamadia L.E., Remmerswaal E.B., Surachno S., Lardy N.M., Wertheim-Van Dillen P.M., Van Lier R.A.W., et al. Cross-reactivity of cytomegalovirus-specific CD8+ T cells to allo-major histocompatibility complex class I molecules. Transplantation 2004, 77:1879-1885.
75. Koelle D.M., Chen H.B., McClurkan C.M., Petersdorf E.W. Herpes simplex virus type 2-specific CD8 cytotoxic T lymphocyte cross-reactivity against prevalent HLA class I alleles. Blood 2002, 99:3844-3847.
76. Landais E., Morice A., Long H.M., Haigh T.A., Charreau B., Bonneville M., et al. EBV-specific CD4+ T cell clones exhibit vigorous allogeneic responses. J Immunol 2006, 177:1427-1433.
77. Amir A.L., D'Orsogna L.J., Roelen D.L., van Loenen M.M., Hagedoorn R.S., de Boer R., et al. Allo-HLA reactivity of virus-specific memory T cells is common. Blood 2010, 115:3146-3157.
78. D'Orsogna L.J., Roelen D.L., Doxiadis I.I., Claas F.H. Screening of viral specific T-cell lines for HLA alloreactivity prior to adoptive immunotherapy may prevent GvHD. Transpl Immunol 2011, 24:141.
79. Morice A., Charreau B., Neveu B., Brouard S., Soulillou J.P., Bonneville M., et al. Cross-reactivity of herpesvirus-specific CD8 T cell lines toward allogeneic class I MHC molecules. PLoS One 2010, 5:e12120.
80. Amir A.L., van der Steen D.M., Hagedoorn R.S., Kester M.G., van Bergen C.A., Drijfhout J.W., et al. Allo-HLA-reactive T cells inducing graft-versus-host disease are single peptide specific. Blood 2011, 118:6733-6742.
81. Deckers J.G.M., Daha M.R., Van Der Kooij S.W., Van Der Woude F.J. Epithelial- and endothelial-cell specificity of renal graft infiltrating T cells. Clin Transplant 1998, 12:285-291.
82. Yard B.A., Claas F.H.J., Paape M.E., Bruijn J.A., Daha M.R., Van Es L.A., et al. Recognition of a tissue-specific polymorphism by graft infiltrating T-cell clones isolated from a renal allograft with acute rejection. Nephrol Dial Transplant 1994, 9:805-810.
83. Deckers J.G.M., Boonstra J.G., Van Der Kooij S.W., Daha M.R., Van Der Woude F.J. Tissue-specific characteristics of cytotoxic graft-infiltrating T cells during renal allograft rejection. Transplantation 1997, 64:178-181.
84. D'Orsogna L.J., Roelen D.L., van der Meer-Prins E.M., van der Pol P., Franke-van Dijk M.E., Eikmans M., et al. Tissue specificity of cross-reactive allogeneic responses by EBV EBNA3A-specific memory T cells. Transplantation 2011, 91:494-500.
85. Schnyder B., Adam J., Rauch A., Thurnheer M.C., Pichler W.J. HLA-B*57:01(+) abacavir-naive individuals have specific T cells but no patch test reactivity. J Allergy Clin Immunol 2013, 132:756-758.
86. Mackay L.K., Wakim L., van Vliet C.J., Jones C.M., Mueller S.N., Bannard O., et al. Maintenance of T cell function in the face of chronic antigen stimulation and repeated reactivation for a latent virus infection. J Immunol 2012, 188:2173-2178.
87. Lang A., Brien J.D., Nikolich-Zugich J. Inflation and long-term maintenance of CD8 T cells responding to a latent herpesvirus depend upon establishment of latency and presence of viral antigens. J Immunol 2009, 183:8077-8087.
88. Lang A., Nikolich-Zugich J. Functional CD8 T cell memory responding to persistent latent infection is maintained for life. J Immunol 2011, 187:3759-3768.
89. Allam A., Conze D.B., Giardino Torchia M.L., Munitic I., Yagita H., Sowell R.T., et al. The CD8+ memory T-cell state of readiness is actively maintained and reversible. Blood 2009, 114:2121-2130.
90. Brehm M.A., Pinto A.K., Daniels K.A., Schneck J.P., Welsh R.M., Selin L.K. T cell immunodominance and maintenance of memory regulated by unexpectedly cross-reactive pathogens. Nat Immunol 2002, 3:627-634.
91. Gray D., Matzinger P. T cell memory is short-lived in the absence of antigen. J Exp Med 1991, 174:969-974.
92. Genin E., Schumacher M., Roujeau J.C., Naldi L., Liss Y., Kazma R., et al. Genome-wide association study of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe. Orphanet J Rare Dis 2011, 6:52.
93. Hung S.I., Chung W.H., Liou L.B., Chu C.C., Lin M., Huang H.P., et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005, 102:4134-4139.
94. Lonjou C., Borot N., Sekula P., Ledger N., Thomas L., Halevy S., et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008, 18:99-107.
95. Somkrua R., Eickman E.E., Saokaew S., Lohitnavy M., Chaiyakunapruk N. Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. BMC Med Genet 2011, 12:118.
96. Tassaneeyakul W., Jantararoungtong T., Chen P., Lin P.Y., Tiamkao S., Khunarkornsiri U., et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 2009, 19:704-709.
97. Cristallo A.F., Schroeder J., Citterio A., Santori G., Ferrioli G.M., Rossi U., et al. A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis. Int J Immunogenet 2011, 38:303-309.
98. Kang H.R., Jee Y.K., Kim Y.S., Lee C.H., Jung J.W., Kim S.H., et al. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics 2011, 21:303-307.
99. Ramasamy S.N., Korb-Wells C.S., Kannangara D.R., Smith M.W., Wang N., Roberts D.M., et al. Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012. Drug Saf 2013, 36:953-980.
100. Goncalo M., Coutinho I., Teixeira V., Gameiro A.R., Brites M.M., Nunes R., et al. HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population. Br J Dermatol 2013, 169:660-665.
101. Locharernkul C., Loplumlert J., Limotai C., Korkij W., Desudchit T., Tongkobpetch S., et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 2008, 49:2087-2091.
102. Man C.B., Kwan P., Baum L., Yu E., Lau K.M., Cheng A.S., et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007, 48:1015-1018.
103. Wang Q., Zhou J.Q., Zhou L.M., Chen Z.Y., Fang Z.Y., Chen S.D., et al. Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland. Seizure 2011, 20:446-448.
104. Wu X.T., Hu F.Y., An D.M., Yan B., Jiang X., Kwan P., et al. Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China. Epilepsy Behav 2010, 19:405-408.
105. Zhang Y., Wang J., Zhao L.M., Peng W., Shen G.Q., Xue L., et al. Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients. Eur J Clin Pharmacol 2011, 67:885-887.
106. Chang C.C., Too C.L., Murad S., Hussein S.H. Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population. Int J Dermatol 2011, 50:221-224.
107. Tangamornsuksan W., Chaiyakunapruk N., Somkrua R., Lohitnavy M., Tassaneeyakul W. Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol 2013, 149:1025-1032.
108. Cheung Y.K., Cheng S.H., Chan E.J., Lo S.V., Ng M.H., Kwan P. HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Epilepsia 2013, 54:1307-1314.
109. Kaniwa N., Saito Y., Aihara M., Matsunaga K., Tohkin M., Kurose K., et al. HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia 2010, 51:2461-2465.
110. Ikeda H., Takahashi Y., Yamazaki E., Fujiwara T., Kaniwa N., Saito Y., et al. HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions. Epilepsia 2010, 51:297-300.
111. Niihara H., Kakamu T., Fujita Y., Kaneko S., Morita E. HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population. J Dermatol 2011, 39:594-601.
112. Hung S.I., Chung W.H., Liu Z.S., Chen C.H., Hsih M.S., Hui R.C., et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 2010, 11:349-356.
113. An D.M., Wu X.T., Hu F.Y., Yan B., Stefan H., Zhou D. Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B*1502 in a Han Chinese population. Epilepsy Res 2010, 92:226-230.
114. Shi Y.W., Min F.L., Liu X.R., Zan L.X., Gao M.M., Yu M.J., et al. Hla-B alleles and lamotrigine-induced cutaneous adverse drug reactions in the Han Chinese population. Basic Clin Pharmacol Toxicol 2011, 109:42-46.
115. Kaniwa N., Sugiyama E., Saito Y., Kurose K., Maekawa K., Hasegawa R., et al. Specific HLA types are associated with antiepileptic drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese subjects. Pharmacogenomics 2013, 14:1821-1831.
116. Roujeau J.C., Huynh T.N., Bracq C., Guillaume J.C., Revuz J., Touraine R. Genetic susceptibility to toxic epidermal necrolysis. Arch Dermatol 1987, 123:1171-1173.
117. Lee H.Y., Lie D., Lim K.S., Thirumoorthy T., Pang S.M. Strontium ranelate-induced toxic epidermal necrolysis in a patient with post-menopausal osteoporosis. Osteoporos Int 2009, 20:161-162.
118. Musette P., Brandi M.L., Cacoub P., Kaufman J.M., Rizzoli R., Reginster J.Y. Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity. Osteoporos Int 2010, 21:723-732.
119. Kaniwa N., Saito Y., Aihara M., Matsunaga K., Tohkin M., Kurose K., et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008, 9:1617-1622.
120. Tohkin M., Kaniwa N., Saito Y., Sugiyama E., Kurose K., Nishikawa J., et al. A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Pharmacogenomics J 2011, 13:60-69.
121. Chiu L., Hu M., Ng M., Yeung C., Chan J., Chang M., et al. Association between HLA-B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong. Br J Dermatol 2012, 167:44-49.
122. Phillips E, Keane N, Blyth C, Lucas A, Pavlos R, Lucas M, et al. Both HLA Class I restricted CD8+ and class II restricted CD4+ T cells are implicated in the pathogenesis of nevirapine hypersensitivity. 51st ICAAC. Chicago, Ill; September 2011:H1-1399c.
123. Alfirevic A., Jorgensen A.L., Williamson P.R., Chadwick D.W., Park B.K., Pirmohamed M. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 2006, 7:813-818.
124. Pirmohamed M., Lin K., Chadwick D., Park B.K. TNF alpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients. Neurology 2001, 56:890-896.
125. Jonville-Bera A.P., Crickx B., Aaron L., Hartingh I., Autret-Leca E. Strontium ranelate-induced DRESS syndrome: first two case reports. Allergy 2009, 64:658-659.
126. Zhang F.R., Liu H., Irwanto A., Fu X.A., Li Y., Yu G.Q., et al. HLA-B*13:01 and the dapsone hypersensitivity syndrome. N Engl J Med 2013, 369:1620-1628.
127. Vitezica Z.G., Milpied B., Lonjou C., Borot N., Ledger T.N., Lefebvre A., et al. HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS 2008, 22:540-541.
128. Chantarangsu S., Mushiroda T., Mahasirimongkol S., Kiertiburanakul S., Sungkanuparph S., Manosuthi W., et al. HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet Genomics 2009, 19:139-146.
129. Chantarangsu S., Mushiroda T., Mahasirimongkol S., Kiertiburanakul S., Sungkanuparph S., Manosuthi W., et al. Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash. Clin Infect Dis 2011, 53:341-348.
130. Romano A., De Santis A., Romito A., Di Fonso M., Venuti A., Gasbarrini G.B., et al. Delayed hypersensitivity to aminopenicillins is related to major histocompatibility complex genes. Ann Allergy Asthma Immunol 1998, 80:433-437.
131. Hu F.Y., Wu X.T., An D.M., Yan B., Stefan H., Zhou D. Pilot association study of oxcarbazepine-induced mild cutaneous adverse reactions with HLA-B*1502 allele in Chinese Han population. Seizure 2011, 20:160-162.
132. Lv Y.D., Min F.L., Liao W.P., He N., Zeng T., Ma D.H., et al. The association between oxcarbazepine-induced maculopapular eruption and HLA-B alleles in a northern Han Chinese population. BMC Neurol 2013, 13:75.
133. Hautekeete M.L., Horsmans Y., Van Waeyenberge C., Demanet C., Henrion J., Verbist L., et al. HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology 1999, 117:1181-1186.
134. Lucena M.I., Molokhia M., Shen Y., Urban T.J., Aithal G.P., Andrade R.J., et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011, 141:338-347.
135. O'Donohue J., Oien K.A., Donaldson P., Underhill J., Clare M., MacSween R.N., et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 2000, 47:717-720.
136. Singer J.B., Lewitzky S., Leroy E., Yang F., Zhao X., Klickstein L., et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet 2010, 42:711-714.
137. Kindmark A., Jawaid A., Harbron C.G., Barratt B.J., Bengtsson O.F., Andersson T.B., et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 2008, 8:186-195.
138. Daly A.K., Aithal G.P., Leathart J.B., Swainsbury R.A., Dang T.S., Day C.P. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 2007, 132:272-281.
139. Daly A.K., Day C.P. Genetic association studies in drug-induced liver injury. Semin Liver Dis 2009, 29:400-411.
140. Daly A.K., Day C.P. Genetic association studies in drug-induced liver injury. Drug Metab Rev 2012, 44:116-126.
141. Daly A.K., Donaldson P.T., Bhatnagar P., Shen Y., Pe'er I., Floratos A., et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009, 41:816-819.
142. Spraggs C.F., Budde L.R., Briley L.P., Bing N., Cox C.J., King K.S., et al. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol 2011, 29:667-673.
143. Pellicano R., Ciavarella G., Lomuto M., Di Giorgio G. Genetic susceptibility to fixed drug eruption: evidence for a link with HLA-B22. J Am Acad Dermatol 1994, 30:52-54.
144. Pellicano R., Lomuto M., Ciavarella G., Di Giorgio G., Gasparini P. Fixed drug eruptions with feprazone are linked to HLA-B22. J Am Acad Dermatol 1997, 36:782-784.
145. Ozkaya-Bayazit E., Akar U. Fixed drug eruption induced by trimethoprim-sulfamethoxazole: evidence for a link to HLA-A30 B13 Cw6 haplotype. J Am Acad Dermatol 2001, 45:712-717.
146. Lieberman J.A., Yunis J., Egea E., Canoso R.T., Kane J.M., Yunis E.J. HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatry 1990, 47:945-948.
147. Valevski A., Klein T., Gazit E., Meged S., Stein D., Elizur A., et al. HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients. Eur J Immunogenet 1998, 25:11-13.
148. Athanasiou M.C., Dettling M., Cascorbi I., Mosyagin I., Salisbury B.A., Pierz K.A., et al. Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. J Clin Psychiatry 2011, 72:458-463.
149. Dettling M., Cascorbi I., Opgen-Rhein C., Schaub R. Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens. Pharmacogenomics J 2007, 7:325-332.
150. Diez R.A. HLA-B27 and agranulocytosis by levamisole. Immunol Today 1990, 11:270.
151. Batchelor J.R., Welsh K.I., Tinoco R.M., Dollery C.T., Hughes G.R., Bernstein R., et al. Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility. Lancet 1980, I:1107-1109.
152. Vedove C.D., Del Giglio M., Schena D., Girolomoni G. Drug-induced lupus erythematosus. Arch Dermatol Res 2009, 301:99-105.
153. Kim S.H., Hur G.Y., Choi J.H., Park H.S. Pharmacogenetics of aspirin-intolerant asthma. Pharmacogenomics 2008, 9:85-91.
154. Rodriguez-Perez M., Gonzalez-Dominguez J., Mataran L., Garcia-Perez S., Salvatierra D. Association of HLA-DR5 with mucocutaneous lesions in patients with rheumatoid arthritis receiving gold sodium thiomalate. J Rheumatol 1994, 21:41-43.
155. Speerstra F., Reekers P., van de Putte L.B., Vandenbroucke J.P. HLA associations in aurothioglucose- and D-penicillamine-induced haematotoxic reactions in rheumatoid arthritis. Tissue Antigens 1985, 26:35-40.
156. Quiralte J., Sanchez-Garcia F., Torres M.J., Blanco C., Castillo R., Ortega N., et al. Association of HLA-DR11 with the anaphylactoid reaction caused by nonsteroidal anti-inflammatory drugs. J Allergy Clin Immunol 1999, 103:685-689.
157. Garlepp M.I., Dawkins R.L., Christiansen F.T. HLA antigens and acetylcholine receptor antibodies in penicillamine induced myasthenia gravis. Br Med J (Clin Res Ed) 1983, 286:1442-1443.
158. Pachoula-Papasteriades C., Boki K., Varla-Leftherioti M., Kappos-Rigatou I., Fostiropoulos G., Economidou J. HLA-A,-B, and -DR antigens in relation to gold and D-penicillamine toxicity in Greek patients with RA. Dis Markers 1986, 4:35-41.
159. Maier L.A., McGrath D.S., Sato H., Lympany P., Welsh K., Du Bois R., et al. Influence of MHC class II in susceptibility to beryllium sensitization and chronic beryllium disease. J Immunol 2003, 171:6910-6918.
160. Rosenman K.D., Rossman M., Hertzberg V., Reilly M.J., Rice C., Kanterakis E., et al. HLA class II DPB1 and DRB1 polymorphisms associated with genetic susceptibility to beryllium toxicity. Occup Environ Med 2011, 68:487-493.
161. Morito H., Kitamura K., Fukumoto T., Kobayashi N., Kuwahara M., Asada H. Drug eruption with eosinophilia and systemic syndrome associated with reactivation of human herpesvirus 7, not human herpesvirus 6. J Dermatol 2012, 39:669-670.
162. Descamps V., Bouscarat F., Laglenne S., Aslangul E., Veber B., Descamps D., et al. Human herpesvirus 6 infection associated with anticonvulsant hypersensitivity syndrome and reactive haemophagocytic syndrome. Br J Dermatol 1997, 137:605-608.
163. Kawakami T., Fujita A., Takeuchi S., Muto S., Soma Y. Drug-induced hypersensitivity syndrome: drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome induced by aspirin treatment of Kawasaki disease. J Am Acad Dermatol 2009, 60:146-149.
164. Hamaguchi Y., Fujimoto M., Enokido Y., Wayaku T., Kaji K., Echigo T., et al. Intractable genital ulcers from herpes simplex virus reactivation in drug-induced hypersensitivity syndrome caused by allopurinol. Int J Dermatol 2010, 49:700-704.
165. Mardivirin L., Valeyrie-Allanore L., Branlant-Redon E., Beneton N., Jidar K., Barbaud A., et al. Amoxicillin-induced flare in patients with DRESS (drug reaction with eosinophilia and systemic symptoms): report of seven cases and demonstration of a direct effect of amoxicillin on Human Herpesvirus 6 replication in vitro. Eur J Dermatol 2010, 20:68-73.
166. Tamagawa-Mineoka R., Katoh N., Nara T., Nishimura Y., Yamamoto S., Kishimoto S. DRESS syndrome caused by teicoplanin and vancomycin, associated with reactivation of human herpesvirus-6. Int J Dermatol 2007, 46:654-655.
167. Draz N., Datta S., Webster D.P., Cropley I. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome secondary to antituberculosis drugs and associated with human herpes virus-7 (HHV-7). BMJ Case Rep. July 31, 2013, pii: bcr2013010348. doi: 10.1136/bcr-2013-010348.
168. Funck-Brentano E., Duong T., Family D., Bouaziz J.D., Ortonne N., Bagot M., et al. Auto-immune thyroiditis and drug reaction with eosinophilia and systemic symptoms (DRESS) associated with HHV-6 viral reactivation [in French with English abstract]. Ann Dermatol Venereol 2011, 138:580-585.
169. Sandouk Z., Alirhayim Z., Khoulani D., Hassan S. DRESS syndrome and thrombotic thrombocytopaenic purpura: are they relatedα. BMJ Case Rep. November 14, 2012, pii: bcr2012007558. doi: 10.1136/bcr-2012-007558.
170. Kinyo A., Belso N., Nagy N., Palvolgyi A., Nagy I., Korom I., et al. Strontium ranelate-induced DRESS syndrome with persistent autoimmune hepatitis. Acta Derm Venereol 2011, 91:205-206.
171. Bejia I., Ben Hammouda S., Riahi K., Zinelabidine F., Mediouni B., Touzi M., et al. DRESS syndrome induced by sulphasalazine in rheumatoid arthritis. Joint Bone Spine 2006, 73:764-765.
172. Michel F., Navellou J.C., Ferraud D., Toussirot E., Wendling D. DRESS syndrome in a patient on sulfasalazine for rheumatoid arthritis. Joint Bone Spine 2005, 72:82-85.
173. Pinana E., Lei S.H., Merino R., Melgosa M., De La Vega R., Gonzales-Obeso E., et al. DRESS-syndrome on sulfasalazine and naproxen treatment for juvenile idiopathic arthritis and reactivation of human herpesvirus 6 in an 11-year-old Caucasian boy. J Clin Pharm Ther 2010, 35:365-370.